Science platform ResearchGate launches COVID-19 community
Reuters
Published Apr 06, 2020 09:55AM ET
BERLIN (Reuters) - ResearchGate, a social network site for scientists and researchers, has launched a new forum to facilitate collaboration between COVID-19 experts on research into beating the flu-like disease caused by the novel coronavirus.
The site https://www.researchgate.net/community/COVID-19/discussions, developed in 10 days and launched late last week, boosts the visibility of articles, pre-prints and research proposals, as well as offering an expert finder https://www.researchgate.net/COVID-19?utm_source=logged_out_community&utm_medium=RG#contact-form to help build international or interdisciplinary project teams.
"We have 11,000 COVID-19 researchers on ResearchGate - there are huge potential network effects between these scientists," said Ijad Madisch, founder and CEO of the Berlin-based startup that has come to be known as 'Facebook (NASDAQ:FB) for scientists'.
ResearchGate, which is backed among others by Microsoft (NASDAQ:MSFT) founder Bill Gates and investment bank Goldman Sachs (NYSE:GS), has stirred up the staid world of scientific publishing by making it easier to share research that hasn't yet been subjected to peer review.
The COVID-19 research community features contributions, sorted by the newest, most read or most recommended, as well as an interactive question and answer panel to debate hot topics. Content moderation will follow soon, added Madisch.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.